A randomized open-label DESTINY-breast04 phase III trial was performed to evaluate T-DXd in HER2-low patients with unresectable or metastatic BC who were previously treated with one or two prior lines of chemotherapy [24]. The gene discussed is ERBB2; the disease is breast cancer.